| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/05/2001 | WO2001047880A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047879A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | WO2001047875A1 Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone |
| 07/05/2001 | WO2001047859A1 Compounds active at the glucocorticoid receptor |
| 07/05/2001 | WO2001047564A2 Labelled ascorbic acid derivatives |
| 07/05/2001 | WO2001047562A2 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 07/05/2001 | WO2001047561A1 Hyaluronic acid in the treatment of cancer |
| 07/05/2001 | WO2001047552A1 Polysialic acid-klh conjugate vaccine |
| 07/05/2001 | WO2001047546A2 Methods and products for tumor immunotherapy using cytokines |
| 07/05/2001 | WO2001047543A2 Activation and inhibition of the immune system |
| 07/05/2001 | WO2001047533A2 INHIBITION OF GSK-3$g(b) |
| 07/05/2001 | WO2001047514A1 Use of hypoglycemic agent for treating impaired glucose metabolism |
| 07/05/2001 | WO2001047507A2 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
| 07/05/2001 | WO2001047505A2 Use of azoles for preventing skin cancer |
| 07/05/2001 | WO2001047490A1 Devices for the delivery of drugs having antiprogestinic properties |
| 07/05/2001 | WO2001040446A8 Pour-on formulations |
| 07/05/2001 | WO2001012592A3 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 07/05/2001 | WO2001003720A9 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 07/05/2001 | WO2001002019A3 Control of gene expression |
| 07/05/2001 | WO2001000824A3 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 07/05/2001 | WO2001000822A3 Cdna sequences of two interacting fancip2 and fancip3 of the fanconi anemia complementation group a protein |
| 07/05/2001 | WO2000073478A3 Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| 07/05/2001 | WO2000073348A3 Methods and compositions for inhibiting neoplastic cell growth |
| 07/05/2001 | WO2000070046A3 Secreted polypeptides and corresponding polynucleotides |
| 07/05/2001 | WO2000068195A3 Substituted pyrrolidines as cell adhesion inhibitors |
| 07/05/2001 | WO2000061622A3 Genes associated with diseases of the kidney |
| 07/05/2001 | WO2000059942A3 Human obesity protein binding protrein-2 homolog and uses thereof |
| 07/05/2001 | WO2000055137A8 Compounds and methods for modulation of estrogen receptors |
| 07/05/2001 | WO2000052134A3 Inhibitors of prenyl-protein transferase |
| 07/05/2001 | WO2000023114A9 Polymer conjugates of interferon beta- 1a and their uses |
| 07/05/2001 | WO2000018799A9 Artemin, a novel neurotrophic factor |
| 07/05/2001 | WO1999053910A8 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 07/05/2001 | US20010007152 Obtained by immunizing transgenic mice which produce human leukocyte antigen (HLA) with tumor-associated antigens and recovering the nucleic acids encoding the T cell receptors from the cytotoxic T lymphocytes; diagnosis and therapy |
| 07/05/2001 | US20010007025 Antisense modulation of bcl-x expression |
| 07/05/2001 | US20010007022 An antibody which binds procalcitonin but not free calcitonin, free katacalcin and free N-procalcitonin; used as an in vitro or in vivo diagnostic agent |
| 07/05/2001 | US20010007020 Antibodies that bind to the nidogen-binding domain of laminin, their production and use |
| 07/05/2001 | US20010006974 Combination therapy for lymphoproliferative diseases |
| 07/05/2001 | US20010006973 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels |
| 07/05/2001 | US20010006966 Use of 1- (aminoalkyl) -3-quinoxaline-2-on derivatives for the preparation of compounds having an antioxidant action |
| 07/05/2001 | US20010006962 Behavior of biologically active compounds favorably modified by replacing a functional group with an unsaturated fatty derivative, e.g. elaidic acid; bioavailability; membrane passage; organ targeting; drugs; agriculture |
| 07/05/2001 | US20010006957 Microdispersed or microfibrillar polyanhydroglucuronic acids and salts, complex salts or intermolecular polymer complexes suitable for fixing drug dosages with significantly protracted effect and reduced toxicity |
| 07/05/2001 | US20010006954 Synthetic DNA comprising a radiation responsive enhancer-promoter operatively linked to a polypeptide encoding region linked to a transcription terminating region; regulating gene expression and inhibiting tumor growth |
| 07/05/2001 | US20010006940 Human chorionic gonadotrophin (hCG) used to treat or prevent tumors, multiple sclerosis, inflammation or angiogenesis-dependent diseases |
| 07/05/2001 | US20010006686 Extract; antiinflammatory agent for treatment of cyclooxygenase-2 (COX-2) conditions such as arthritis, pain from cancer; selective inhibition of COX-2 over COX-1 |
| 07/05/2001 | US20010006642 Delivering antigens or biologically active polypeptides to a subject in need of same by administering to the subject a non-invasive or non-pathogenic bacterium which expresses the antigens or polypeptides |
| 07/05/2001 | US20010006640 Compounds and methods to inhibit or augment an inflammatory response |
| 07/05/2001 | US20010006633 Adenovirus-chemotherapeutic combination for treating cancer |
| 07/05/2001 | US20010006631 Alloactivated lymphocytes in a pharmaceutical excipient; immunotherapy |
| 07/05/2001 | US20010006616 Polymeric delivery of radionuclides and radiopharmaceuticals |
| 07/05/2001 | US20010005930 Method of making a hollow-tube precursor brachytherapy device |
| 07/05/2001 | DE19963235A1 Substituierte Piperazinderivate, ihre Herstellung und ihre Verwendung als Arzneimittel Substituted piperazine derivatives, their preparation and their use as medicaments |
| 07/05/2001 | DE19962924A1 Substituierte Oxazolidinone und ihre Verwendung Substituted oxazolidinones and their use |
| 07/05/2001 | CA2699568A1 Azaindoles |
| 07/05/2001 | CA2396693A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | CA2396579A1 Tricyclic protein kinase inhibitors |
| 07/05/2001 | CA2396039A1 Gfr.alpha.1-ret specific agonists and methods therefor |
| 07/05/2001 | CA2396029A1 Use of a native epitope for selecting evolved binding members from a library of mutants of a protein capable of binding to said epitope |
| 07/05/2001 | CA2395716A1 Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone |
| 07/05/2001 | CA2395663A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | CA2395575A1 Uses of transport proteins for controlling cell cycle |
| 07/05/2001 | CA2395543A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | CA2395535A1 Method for the production of vitamin a |
| 07/05/2001 | CA2395524A1 Chemotherapeutant screening method |
| 07/05/2001 | CA2395454A1 Viral core protein-cationic lipid-nucleic acid-delivery complexes |
| 07/05/2001 | CA2395345A1 Use of azoles for preventing skin cancer |
| 07/05/2001 | CA2395320A1 Therapeutic uses of lna-modified oligonucleotides |
| 07/05/2001 | CA2395284A1 Inhibition of gsk-3.beta. |
| 07/05/2001 | CA2395275A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof |
| 07/05/2001 | CA2395259A1 Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect |
| 07/05/2001 | CA2395236A1 Basolateral sorting signal and inhibitors thereof |
| 07/05/2001 | CA2395205A1 2-(1h-indol-3-yl)-2-oxo-acetamides with antitumor activity |
| 07/05/2001 | CA2395179A1 Nitrile derivatives as cathepsin k inhibitors |
| 07/05/2001 | CA2395173A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | CA2395003A1 Dioxygenases catalyzing the asymetric cleavage of beta-carotene |
| 07/05/2001 | CA2394959A1 Labelled ascorbic acid derivatives |
| 07/05/2001 | CA2394944A1 Combinations of a receptor tyrosine kinase inhibitor with an organic compound capable of binding to .alpha.1-acidic glycoprotein |
| 07/05/2001 | CA2394880A1 Activation and inhibition of the immune system |
| 07/05/2001 | CA2394727A1 Pyrimidine and triazine kinase inhibitors |
| 07/05/2001 | CA2394644A1 Substituted piperazine derivatives,the preparation thereof and their useas medicaments |
| 07/05/2001 | CA2394295A1 Antibodies against plasma cells |
| 07/05/2001 | CA2394174A1 A molecular switch for regulating mammalian gene expression |
| 07/05/2001 | CA2393583A1 Compounds active at the glucocorticoid receptor |
| 07/05/2001 | CA2392703A1 Human heparanase-related polypeptide and nucleic acid |
| 07/04/2001 | EP1113020A2 Nucleosides and oligonucleotides containing boron clusters |
| 07/04/2001 | EP1113007A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| 07/04/2001 | EP1112497A1 Ykl-40 as a marker and prognostic indicator for cancers |
| 07/04/2001 | EP1112371A1 Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| 07/04/2001 | EP1112364A2 Stomach polypeptide zsig28 |
| 07/04/2001 | EP1112361A2 Promotion or inhibition of angiogenesis and cardiovascularization |
| 07/04/2001 | EP1112358A2 Dna sequence encoding oncofetal ferritin protein |
| 07/04/2001 | EP1112356A1 Inhibitor of brn-3b and its use for the treatment of breast and ovarian cancers |
| 07/04/2001 | EP1112286A1 Secreted proteins and polynucleotides encoding them |
| 07/04/2001 | EP1112284A1 Piperazine-4-phenyl derivatives as inhibitors of the interaction between mdm2 and p53 |
| 07/04/2001 | EP1112267A2 Inhibition of oncogene transcription by synthetic polyamides |
| 07/04/2001 | EP1112262A1 SUBSTITUTED $g(g)-PHENYL-$g(D)-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO |
| 07/04/2001 | EP1112251A1 Azetidine derivatives, preparation and medicines containing them |
| 07/04/2001 | EP1112250A1 Therapeutic compounds and methods |
| 07/04/2001 | EP1112086A1 Antibodies to c3b(i) for delivery of diagnostic and therapeutic agents to cancer cells |
| 07/04/2001 | EP1112084A1 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| 07/04/2001 | EP1112080A1 REGULATION OF HER2/neu ONCOGENE EXPRESSION BY SYNTHETIC POLYAMIDES |